| 000 | 01794 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513213111.0 | ||
| 264 | 0 | _c20000713 | |
| 008 | 200007s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/S0140-6736(00)02293-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDouek, D C | |
| 245 | 0 | 0 |
_aAssessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cMay 2000 |
||
| 300 |
_a1875-81 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntigens, CD _ximmunology |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aGene Rearrangement, T-Lymphocyte |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xadministration & dosage |
| 650 | 0 | 4 | _aHematopoietic Stem Cell Transplantation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLymphocyte Count |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Myeloma _xdrug therapy |
| 650 | 0 | 4 |
_aMyeloablative Agonists _xadministration & dosage |
| 650 | 0 | 4 |
_aReceptors, Antigen, T-Cell _ximmunology |
| 650 | 0 | 4 | _aT-Lymphocytes |
| 650 | 0 | 4 |
_aThymus Gland _ximmunology |
| 650 | 0 | 4 | _aTransplantation Conditioning |
| 700 | 1 | _aVescio, R A | |
| 700 | 1 | _aBetts, M R | |
| 700 | 1 | _aBrenchley, J M | |
| 700 | 1 | _aHill, B J | |
| 700 | 1 | _aZhang, L | |
| 700 | 1 | _aBerenson, J R | |
| 700 | 1 | _aCollins, R H | |
| 700 | 1 | _aKoup, R A | |
| 773 | 0 |
_tLancet (London, England) _gvol. 355 _gno. 9218 _gp. 1875-81 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(00)02293-5 _zAvailable from publisher's website |
| 999 |
_c10817276 _d10817276 |
||